RSS Feeds
Search

Press releases

Press releases

Displaying 11..20 of 26 - per page Previous page Next page
Order by
AMARIN REPORTS INITIATION OF ENROLLMENT AND FIRST PATIENT DOSING IN PIVOTAL PHASE III CLINICAL TRIALS FOR MIRAXION IN HUNTINGTON'S DISEASE More
Amarin announces results from pre-clinical research conducted at Trinity College, Dublin More
Consistent data in three Phase IIa clinical trials in depression patients with melancholic characteristics More
Astex Technology , today announced issuance of patent GB2395718 covering the use of the crystal structure of human cytochrome P450 3A4. More
Astex Technology announced that its scientists had published the 3-dimensional structure of human cytochrome P450 3A4. More
2005 Third quarter financial results and corporate developments. More
Novozymes has discovered Plectasin, an antimicrobial peptide (AMP) that acts on bacterial infections that have developed resistance to conventional antibiotics. More
American Pharmaceutical Partners, Inc. today said that a New Drug Submission for ABRAXANE(tm) has been filed with the Therapeutic Products Directorate (TPD) of Health Canada. More
Bone fracture and osteoporosis prevention and treatment composition SO101C, discovered and developed by Sagittarius Life Science Corp., recently completed Phase II clinical trials, the company announced today. More
Foamix Ltd. announced today that on November 22, 2005 the United States Patent and Trademark Office (USPTO) issued to Foamix Patent No. 6,967,023. More
Displaying 11..20 of 26 - per page Previous page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Dec 2008 - 35 pages - $200
Aug 2010 - 33 pages - $250
Aug 2010 - 36 pages - $250
Mar 2011 - 111 pages - $995
Aug 2010 - 35 pages - $250
Aug 2010 - 38 pages - $250
Mar 2011 - 74 pages - $795
Aug 2010 - 40 pages - $250
Mar 2011 - 73 pages - $795
Aug 2010 - 38 pages - $250

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us